Form 8K Aldeyra Therapeutics Inc For: 17 November By Investing.com
Aldeyra Therapeutics Inc. (ALDX) filed a Form 8K on November 17, 2026, as reported by Investing.com. The filing indicates a significant event or disclosure by the company. The stock price of Aldeyra Therapeutics was down 3.29% at the time of the article.
Aldeyra Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Aldeyra Therapeutics (ALDX) received a notice from Nasdaq on November 17, 2026, indicating that its stock failed to maintain the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has until May 17, 2027, to regain compliance, with the possibility of an additional 180-day period if other requirements are met. This notice does not immediately affect its Nasdaq listing.
Form 4 Aldeyra Therapeutics Inc: Darlene M. Deptula-Hicks (Director) For: 12 November
This article reports on a Form 4 filing for Aldeyra Therapeutics Inc, specifically detailing an insider transaction involving Darlene M. Deptula-Hicks, a Director, for November 12. Form 4 filings are regulatory documents that disclose changes in ownership of company stock by insiders. The article indicates that Aldeyra Therapeutics Inc's stock (ALDX) showed a 4.01% increase.
Aldeyra director Darlene Deptula-Hicks buys $4,875 in stock By Investing.com
Aldeyra Therapeutics director Darlene Deptula-Hicks purchased 7,500 shares of company stock for $4,875 at $0.65 per share on November 12, 2026. This insider acquisition comes as the stock trades near its 52-week low, and InvestingPro analysis suggests the stock is undervalued with a fair value of $0.78. The company is also planning to submit a Formal Dispute Resolution Request to the FDA regarding its dry eye disease treatment, Reproxalap.
Insider Spends US$129k Buying More Shares In Aldeyra Therapeutics
Aldeyra Therapeutics' Independent Chair of the Board, Richard Douglas, recently purchased US$129k worth of shares at US$0.64 each, increasing his holding by 103%. This purchase, along with a larger one by CEO Todd Brady at a higher price last year, indicates insider confidence in the company, despite Aldeyra Therapeutics not having made a profit in the last twelve months. Insiders currently own about 3.6% of the company's stock, suggesting a reasonable alignment with shareholders.
Form 4 Aldeyra Therapeutics Inc: Richard Douglas (Director) For: 11 November
This article reports on a Form 4 filing for Aldeyra Therapeutics Inc., indicating a transaction by Director Richard Douglas. The filing pertains to activity on November 11, with the article published on November 14, 2026.
Aldeyra director Richard Douglas buys $128,899 in company stock By Investing.com
Aldeyra Therapeutics director Richard Douglas recently purchased 200,000 shares of company common stock for approximately $128,899. This transaction, occurring on November 11, 2026, saw shares acquired at a weighted average price of $0.6445, with the stock currently trading near its 52-week low. The company is also pursuing a Formal Dispute Resolution Request with the FDA regarding its dry eye disease treatment, Reproxalap, while H.C. Wainwright maintains a Neutral rating with a $2.00 price target.
Two AQR entities report the same passive stake in Aldeyra Therapeutics (ALDX).
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have each reported a beneficial ownership of 672,616 shares, or 1.11%, of Aldeyra Therapeutics (ALDX) common stock. Both entities hold shared voting and dispositive power over these shares, with AQR Capital Management, LLC being a wholly-owned subsidiary of AQR Capital Management Holdings, LLC. This disclosure was made in an amended Schedule 13G filing with the SEC.
ALDX: Aldeyra Therapeutics Inc. filed SEC Form 8-K: Other Events
Aldeyra Therapeutics Inc. (ALDX) filed an SEC Form 8-K, indicating it has withdrawn its Special Protocol Assessment (SPA) for ADX-2191 in primary vitreoretinal lymphoma (PVRL) and requested the FDA move its Investigational New Drug (IND) review to the hematologic malignancies division. This action creates uncertainty and potential delays for the regulatory path of ADX-2191 and could affect other programs like reproxalap. The company views the transfer as aligning with the FDA's divisional expertise for lymphoma reviews.
Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis
Aldeyra Therapeutics (ALDX) is a clinical-stage biotechnology company developing therapies for immune-mediated and metabolic diseases, with a focus on RASP modulators and an intravitreal methotrexate formulation. Key product candidates include Reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for rare retinal diseases like primary vitreoretinal lymphoma and retinitis pigmentosa. The company's stock has seen significant price changes over the past year, with a one-year change of -86.8%, and its business model relies heavily on the progress and outcomes of its clinical development programs.
Barclays reports a passive stake above 5% in Aldeyra Therapeutics (ALDX).
Barclays PLC has reported a passive stake of 5.48% in Aldeyra Therapeutics, Inc. (ALDX), holding 3,310,587 shares. This disclosure was made via a Schedule 13G filing with the SEC, indicating sole voting and dispositive power over the shares by Barclays and its subsidiaries. The filing was accepted by SEC EDGAR on November 6, 2026, at 02:38 PM EST.
Aldeyra Therapeutics Inc (137.MU) Seasonal returns chart
This article from Yahoo Finance provides a seasonality chart for Aldeyra Therapeutics Inc (137.MU), showing its average monthly price return from 2021 to 2026. The page includes current stock data such as the delayed quote and market status, indicating it is market open. It serves as a financial data resource for investors interested in the stock's historical performance trends.
Aldeyra Therapeutics Inc (137.MU) Seasonal returns chart
This article presents a seasonal returns chart for Aldeyra Therapeutics Inc (137.MU), displaying the average monthly price return between 2021 and 2026. The stock is listed on the Munich exchange with a current price of 0.5150 EUR.
Aldeyra Therapeutics, Inc. (ALDX) Seasonal returns chart
This article provides a seasonal returns chart for Aldeyra Therapeutics, Inc. (ALDX), showing the average monthly price return from 2016 to 2026. It highlights the stock's performance with a current price of 0.5603 USD, a decrease of 14.99% at close on October 30. The page also includes various market data and financial information.
Aldeyra Therapeutics, Inc. Estimates – NASDAQ:ALDX
This page provides financial estimates for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), allowing users to explore reported financial data and analyst estimates across various financial statements. It includes features to compare actual results with average, high, and low estimates and visualize trends over time. The platform explicitly states that the information is not investment advice and encourages users to conduct their own research.
Aldeyra Therapeutics, Inc. (ALDX) Options Chain
This article provides the options chain for Aldeyra Therapeutics, Inc. (ALDX) as of October 16, 2026. It lists call and put options with an expiration date of December 18, 2026, including strike prices, last trade dates, last prices, bid/ask, change, percentage change, volume, open interest, and implied volatility. The data shows various options contracts "In The Money" for both calls and puts.
Which of Upstream Bio (NASDAQ:UPB), Biofrontera (NASDAQ:BFRI), Aldeyra Therapeutics (NASDAQ:ALDX), KALA BIO (NASDAQ:KALA) or Inovio Pharmaceuticals (NASDAQ:INO) Is the Best Biotech or Pharma Gainer in Pre-Market?
This article analyzes the pre-market performance of five biotech and pharma companies: Upstream Bio (UPB), Biofrontera (BFRI), Aldeyra Therapeutics (ALDX), KALA BIO (KALA), and Inovio Pharmaceuticals (INO) on October 16, 2026. Upstream Bio led with a 13.06% gain, driven by sector sentiment rather than specific news. The report highlights that large percentage swings in these low-priced shares are often due to thin liquidity and small market values, suggesting caution for investors.
ROSEN, A LEADING NATIONAL FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is encouraging investors of Aldeyra Therapeutics, Inc. with losses over $100,000 to join a securities class action lawsuit. The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased ALDX securities between November 3, 2023, and March 16, 2026, have until May 29, 2026, to move the Court to serve as lead plaintiff.
Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye
Aldeyra Therapeutics plans to submit a Formal Dispute Resolution Request (FDRR) to the FDA to appeal the Complete Response Letter (CRL) for its dry eye disease drug, reproxalap. The company intends to hold a meeting with the FDA's Office of New Drugs (OND) in Q4 2026, relying on data from nine clinical trials. Aldeyra's cash reserves are projected to last until 2029, providing financial stability through the appeal process.
Aldeyra Therapeutics, Inc. (ALDX) stock price, news, quote and history
Aldeyra Therapeutics, Inc. (ALDX) stock closed at $0.9237, down 21.05%, with a pre-market gain of 1.78%. The biotechnology company is developing therapies for immune-mediated diseases, including reproxalap for dry eye disease and allergic conjunctivitis. The article provides detailed financial data, performance overviews, analyst insights, and company information.
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG
BTIG has maintained its price target for Aldeyra Therapeutics (NASDAQ: ALDX) at $9.00 per share. This indicates the firm's continued outlook on the company's stock performance.
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow (NASDAQ:ALDX) 2026-09-30
Aldeyra Therapeutics, Inc. (ALDX) discussed the FDRR and FDA review process for its drug Reproxalap, which is used for Dry Eye Disease. The company published a slide deck related to this event. This article was written by SA Transcripts, which focuses on publishing quarterly earnings calls and other transcript-related content.
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL
Aldeyra Therapeutics' stock surged after the company announced its intent to file a formal dispute resolution request with the FDA regarding its reproxalap program for dry eye disease. This move follows an FDA Complete Response Letter that cited a lack of substantial evidence for the drug's efficacy. Investors are reacting positively to the company's decision to fight the rejection, seeing it as a company-specific development rather than a broader sector trend.
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease
Aldeyra Therapeutics plans to appeal the FDA's rejection of its investigational drug, reproxalap, for dry eye disease by submitting a Formal Dispute Resolution Request (FDRR). The company will appeal the March 16, 2026 Complete Response Letter which stated that the totality of evidence from completed clinical trials did not support the product's effectiveness, despite Aldeyra's claim of nine adequate trials. Aldeyra expects to submit the FDRR and meet with the FDA's Office of New Drugs in the fourth quarter of 2026.
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics plans to appeal the FDA's rejection of reproxalap for dry eye disease through a formal dispute resolution request. The company argues that the totality of nine clinical trials supports the treatment's effectiveness, despite the FDA's conclusion that the overall evidence was insufficient. Aldeyra expects to meet with the FDA in Q4 2026 and has updated its cash runway guidance to fund operations into 2029, while suspending development of ADX-2191 to conserve resources.
Aldeyra to appeal FDA rejection of dry eye drug reproxalap
Aldeyra Therapeutics plans to appeal the FDA's rejection of its dry eye drug, reproxalap, by submitting a Formal Dispute Resolution Request in Q4 2026. The company seeks to overturn a Complete Response Letter that denied approval, despite having provided data from nine clinical trials. Aldeyra has also updated its financial guidance, extending its operational cash runway into 2029.
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com
This article announces that Aldeyra Therapeutics Inc. filed a Form 8K on September 29. The filing is a standard corporate disclosure that companies submit to the SEC to announce significant events that shareholders should know about.
After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug.
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA regarding its dry eye drug, reproxalap, following three Complete Response Letters denying approval. The company plans to appeal the most recent denial, which cited a lack of sufficient evidence for effectiveness despite nine clinical trials. Aldeyra expects the FDRR submission and a meeting with the FDA's Office of New Drugs in Q4 2026 and has extended its operational cash runway into 2029.
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com
This article announces that Aldeyra Therapeutics Inc. filed a Form 8K on September 29, 2026. The filing is a standard regulatory disclosure for material events that shareholders should know about. The content provides the title of the filing and indicates its publication by Investing.com.
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
Aldeyra Therapeutics announced its intention to file a Formal Dispute Resolution Request with the FDA to appeal the rejection of reproxalap for dry eye disease. This decision follows the third Complete Response Letter from the FDA, which stated the existing clinical trial evidence did not support the drug's effectiveness, though it did not request another trial. Aldeyra expects to submit the request and meet with the FDA's Office of New Drugs in Q4 2026, and has extended its operational cash runway into 2029.
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics plans to submit a Formal Dispute Resolution Request (FDRR) to the FDA regarding its investigational drug reproxalap for dry eye disease, following three Complete Response Letters denying approval. The company aims to appeal the FDA's decision, citing data from nine clinical trials, and anticipates a meeting with the FDA's Office of New Drugs in Q4 2026. Aldeyra also updated its financial guidance, extending its operational cash runway into 2029.
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics announced it will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The webcast will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio webcast and slide presentation will be available on the company's "Investors & Media" section for 90 days following the event.
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The webcast will focus on reproxalap, an investigational drug for dry eye disease. A live audio webcast and slide presentation will be available on the company's website.
Aldeyra Therapeutics, Inc. (ALDX) Options Chain
This page provides the options chain for Aldeyra Therapeutics, Inc. (ALDX), detailing call and put options. As of the data presented, there were no available calls or puts for ALDX. The stock was trading at $1.4650, down 1.01%.
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen
Aldeyra Therapeutics (NASDAQ:ALDX) has been downgraded from a "Hold" to a "Sell" rating by Wall Street Zen, and Weiss Ratings also lowered its assessment. Despite the downgrades, the company met quarterly earnings expectations with a loss of $0.09 per share, and its CEO recently purchased 250,000 shares. Institutional investors and hedge funds hold a significant portion of the company's stock, while analysts maintain a consensus "Hold" rating with an average price target of $5.50.
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake
AQR Capital Management, LLC and its parent company, AQR Capital Management Holdings, LLC, have disclosed a beneficial ownership stake of 6.22% in Aldeyra Therapeutics, Inc. (ALDX), totaling 3,751,558 shares of common stock. Both entities report shared voting power over 3,381,606 shares and shared dispositive power over all 3,751,558 shares. This disclosure, filed under SCHEDULE 13G, indicates a passive investment.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra made false and misleading statements regarding inconsistent results from its reproxalap clinical trials. Investors who suffered losses have until May 29, 2026, to apply to be lead plaintiff.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of clinical trials for their drug candidate, reproxalap. Investors who suffered losses between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 29, 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) who bought securities prior to November 3, 2023. The investigation focuses on whether Aldeyra's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to connect through their website for more information and assistance with the investigation, with no upfront cost to investors.
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Aldeyra Therapeutics Inc (ALDX) has an earnings forecast score of 8.67, ranking 75th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.50, with a strong "Buy" rating based on the consensus of 6 analysts. The company's expected revenue for the next quarter is $24.25 million, and EPS for the next quarter is projected at -$0.10.
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results
Aldeyra Therapeutics (NASDAQ:ALDX) reported a quarterly loss of $0.09 per share, missing analyst estimates by $0.01. Shares dropped 0.6% to $1.59, trading below their moving averages, and the company has a market capitalization of $95.9 million. Despite the earnings miss, CEO Todd C. Brady increased his stake by purchasing 250,000 shares, and analysts maintain a consensus "Hold" rating with a target price of $5.50.
Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary
Aldeyra Therapeutics, Inc. reported a significant reduction in its net loss for Q2 2026, reaching $5.45M compared to $9.77M in Q2 2025, with diluted EPS improving to $(0.09). This improvement is attributed to reduced R&D activity and controlled spending, as the company continues to advance its development programs for reproxalap and ADX-2191. The company maintains an exclusive option with AbbVie for reproxalap commercialization and has sufficient cash to fund operations into the second half of 2028.
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit alleges that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, and suffered losses, have until May 29, 2026, to seek lead plaintiff status.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) on behalf of investors who purchased securities before November 3, 2023, and still hold them. The investigation focuses on whether Aldeyra's officers or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to contact them to learn more about the investigation, noting they operate on a contingency fee basis.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update
Aldeyra Therapeutics (NASDAQ:ALDX) experienced a 36.7% decrease in short interest by July 15th, totaling 3.59 million shares, representing 6.8% of outstanding shares and a two-day days-to-cover ratio. CEO Todd C. Brady recently increased his stake by nearly 17% through a purchase of 250,000 shares valued at $417,500. Analysts maintain a consensus "Hold" rating with a $5.50 price target, despite the stock trading significantly below its 12-month high.
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space
Aldeyra Therapeutics (NASDAQ: ALDX) has signed a lease for a new corporate headquarters located at 23 Bradford Street, Concord, Massachusetts, encompassing approximately 4,067 square feet. The lease, which commences on September 1, 2026, and runs through September 30, 2029, involves an initial monthly base rent of $12,201.00, escalating annually, in addition to operating expenses and taxes. The company will also provide a $50,000.00 security deposit for the new space.
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis
Aldeyra Therapeutics Inc (ALDX) currently holds a valuation score of 8.18, placing it 160th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -3.54, which is significantly below its recent high and above its recent low. Important P/B and P/CF data have not yet been disclosed by the company.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX). The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to come forward and assist in the investigation. They operate on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence
Aldeyra Therapeutics Inc (ALDX) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry. Institutional shareholding increased by 5.38% quarter-over-quarter, reaching 65.57%. Knoll Capital Management, LLC is the largest reported institutional shareholder, holding 5.48M shares.